1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
n/a
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
489-498
Issue
3
Volume
12
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Presence and characteristics of receptors for D-Trp(6) luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer
Publisher
An entity responsible for making the resource available
International Journal of Oncology
Date
A point or period of time associated with an event in the lifecycle of the resource
1998
1998-03
Subject
The topic of the resource
analogs; antagonists; binding-sites; chemotherapy; EGF receptors; estrogen; expression; gnrh; human endometrial carcinoma; LH-RH analogs; LH-RH receptors; Oncology; ovarian-cancer; rat; somatostatin
Creator
An entity primarily responsible for making the resource
Srkalovic G; Schally A V; Wittliff J L; Day T G; Jenison E L
Description
An account of the resource
This study was undertaken to establish the presence and characteristics of receptors for [D-Trp(6)]LH-RH on the membranes of human ovarian cancer. Specific binding of [I-125, D-Trp(6)]LH-RH was found in 29 of 37 (78.4%) ovarian cancers and in 6 of 11 (54.5%) non-malignant human ovaries. Ligand binding was dependent on time and plasma membrane concentration in a fashion expected of a peptide hormone. Saturation, kinetic and displacement data were consistent with the presence of a highly specific, single class of non-cooperative binding site. On the basis of receptors affinity, LH-RH-receptor-positive ovarian cancers could be divided into two groups: high affinity group (K-d=2.7+/-0.60 nM; B-max=0.46+/-0.07 pmol/mg membrane protein) comprising 55% of tumors, and low affinity group (K-d=78.0+/-19.6 nM; B-max=9.44+/-2.68 pmol/mg membrane protein) which included 45% of tumors. LH-RH antagonist Cetrorelix showed an affinity to LH-RH receptors on ovarian cancers 14 times higher than the agonist [D-Trp(6)]LH-RH. Using I-125-epidermal growth factor, specific high affinity receptors were also detected in membranes from 13 of 24 (54%) ovarian cancers and 5 of 11 (45%) non-malignant ovaries. The demonstration of LH-RH receptors in human ovarian cancers provides a rationale for the use of therapeutic approaches based on LH-RH analogues in this malignancy. The probable involvement of growth factors in the development of ovarian cancers suggests the merit of trying a combined therapy based on analogs of LH-RH and somatostatin for this carcinoma.
Identifier
An unambiguous reference to the resource within a given context
n/a
Format
The file format, physical medium, or dimensions of the resource
Journal Article
1998
analogs
antagonists
binding-sites
Chemotherapy
Day T G
EGF receptors
estrogen
expression
gnrh
human endometrial carcinoma
International Journal of Oncology
Jenison E L
Journal Article
LH-RH analogs
LH-RH receptors
oncology
ovarian-cancer
rat
Schally A V
somatostatin
Srkalovic G
Wittliff J L